Innate Announces Interim Results from Phase 2 Study of MIS416 in Secondary Progressive Multiple Sclerosis
Published: Jun 18, 2012
AUCKLAND, New Zealand--(BUSINESS WIRE)--Innate Immunotherapeutics today announced positive interim data from the company’s Phase 1/2 clinical trial of MIS416 in patients with chronic progressive multiple sclerosis (MS). Results of the open-label, dose-escalation/confirmation trial showed MIS416 to be well tolerated and identified a clinical dose for further evaluation. Moreover, during the dose confirmation portion of the study, 8 of 10 patients with secondary progressive MS who were treated with MIS416 for 12 weeks showed some improvement in their MS-related signs and symptoms.